# A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)

> **NCT04449029** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 457 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** GSK3228836
- **DRUG:** Placebo
- **DRUG:** Nucleos(t)ide therapy

## Key facts

- **NCT ID:** NCT04449029
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-27
- **Primary completion:** 2022-03-18
- **Final completion:** 2022-03-18
- **Target enrollment:** 457 (ACTUAL)
- **Last updated:** 2023-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04449029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04449029, "A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04449029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*